Supplementary File 1: Types of provisions in recent regional trade agreements relevant to pharmaceuticals, and location of relevant provisions in chapters, annexes and side instruments

Chapter/provision	ТРР	CPTPP (TPP-11)	СЕТА	USMCA
Intellectual property chapter containing TRIPS-Plus IP provisions	Chapter 18: Intellectual Property	Chapter 18 (some provisions suspended – see Supplementary File 2 for details) Bilateral side letters between some countries regarding pharmaceutical marketing, Article 18.47 and 18.53	Chapter 20: Intellectual Property	Chapter 20: Intellectual Property
Investment protection: Investor-state dispute settlement mechanism; investment chapter with IP covered in definition of investment	Chapter 9: Investment	Incorporates TPP Chapter 9 (slightly narrowed scope) Bilateral side instruments between New Zealand and Australia, Brunei, Malaysia, Peru and Viet Nam	Chapter 8: Investment and Annexes 8-A to 8-F (Chapter 8 suspended until/unless ratified by each EU member state. Following signing of CETA, the ISDS rules were also substantially revised, calling for creation of an 'Investment Court System'.)	Annex 14-D (only applies between Mexico and U.S., scaled back)
Procedural requirements for national pharmaceutical pricing and reimbursement programs	Annex 26-A: Transparency and Procedural Fairness for Pharmaceutical Products and Medical Devices	The specific procedural rules in Annex 26-A Art 3 were suspended by CPTPP Article 2 ¹ (other	N/A	Chapter 29: Publication and Administration, Section B: Transparency and Procedural Fairness for Pharmaceutical Products and

¹ Article 2 of the CPTPP suspends certain provisions of the TPP until they are reinstated by consensus among the Parties.

	(not enforceable	provisions are		Medical
	by state-to-state	retained)		Devices
	•	Tetaineu)		
	dispute			(not
D 11	settlement)	T (enforceable)
Provisions with	Annex 26-A,	Incorporates	N/A	Chapter 29:
implications for	Transparency	TPP Annex		Publication and
regulation of	and Procedural	26-A, Art 4		Administration,
pharmaceutical	Fairness for	(not		Section B:
marketing	Pharmaceutical	enforceable by		Transparency
	Products and	state-to-state		and Procedural
	Medical	dispute		Fairness for
	Devices,	settlement)		Pharmaceutical
	Art 4	,		Products and
	(not enforceable			Medical
	by state-to-state			Devices
	dispute			Art 29.8
	settlement)			(not
	settlement)			•
	<u>Object</u> 10	Observed 10	Olevert 0	enforceable)
	Chapter 10:	Chapter 10:	Chapter 9:	Chapter 15:
	Cross-Border	Cross-Border	Cross-Border	Cross-Border
	Trade in	Trade in	Trade in	Trade in
	Services	Services	Services	Services
Regulatory requirements	Chapter 8:	Incorporates	Chapter 4:	Chapter 11:
for assessing safety,	Technical	TPP Chapter 8	Technical	Technical
efficacy and quality	Barriers to	and Annex 8-C	Barriers to	Barriers to
	Trade and		Trade, and	Trade, and
	Annex 8-C:		Protocol on the	Chapter 12:
	Pharmaceuticals		Mutual	Sectoral
			Recognition of	Annexes -
			the Compliance	Annex 12-F:
			and	Pharmaceuticals
			Enforcement	1 narmaccuticais
			Programme	
			U	
			Regarding	
			Good	
			Manufacturing	
			Practices for	
			Pharmaceutical	
			Products (and	
			associated	
			Annexes 1-3)	
Reduction/elimination of	Chapter 2:	Incorporates	N/A	Chapter 2:
tariffs for	National	TPP Chapter 2		National
	Tational			
bharmaceuticals or their				Treatment and
pharmaceuticals or their ingredients	Treatment and	and Annex 2-D		Treatment and Market Access
pharmaceuticals or their ingredients	Treatment and Market Access			Market Access
-	Treatment and Market Access for Goods			Market Access for Goods
-	Treatment and Market Access for Goods Annex 2-D:			Market Access for Goods (and associated
-	Treatment and Market Access for Goods Annex 2-D: Tariff			Market Access for Goods
-	Treatment and Market Access for Goods Annex 2-D:			Market Access for Goods (and associated
ingredients	Treatment and Market Access for Goods Annex 2-D: Tariff Commitments	and Annex 2-D	Chapter 19:	Market Access for Goods (and associated annexes)
ingredients Rules applying to	Treatment and Market Access for Goods Annex 2-D: Tariff Commitments Chapter 15:	and Annex 2-D Incorporates	Chapter 19: Government	Market Access for Goods (and associated annexes) Chapter 13:
ingredients Rules applying to government procurement	Treatment and Market Access for Goods Annex 2-D: Tariff Commitments Chapter 15: Government	and Annex 2-D Incorporates TPP Chapter	Government	Market Access for Goods (and associated annexes) Chapter 13: Government
ingredients Rules applying to	Treatment and Market Access for Goods Annex 2-D: Tariff Commitments Chapter 15:	and Annex 2-D Incorporates		Market Access for Goods (and associated annexes) Chapter 13:

	Annex 15-A: Government Procurement	15-A with minor changes	Annex 19-A Market Access Schedule of Canada Annex 19-B Market Access Schedule of the European Union	Annex 13-A (Government procurement schedules for Mexico and the US)
Rules applying to state- owned enterprises including pharmaceutical companies	Chapter 17: State-owned Enterprises and Designated Monopolies Annex IV – State-Owned Enterprises and Designated Monopolies Non- Conforming Measures	Incorporates TPP Chapter 17 and Annex IV	Chapter 18: State Enterprises, Monopolies, and Enterprises Granted Special Rights or Privileges	Chapter 22: State-owned Enterprises and associated annexes, and Annex IV: Non- Conforming Activities
Procedural requirements for customs administration and trade facilitation	Chapter 5: Customs Administration and Trade Facilitation	Incorporates TPP Chapter 5	Chapter 6: Customs and Trade Facilitation	Chapter 7: Customs Administration and Trade Facilitation
Rules applying to regulatory practices, cooperation and coherence	Chapter 25: Regulatory Coherence	Incorporates TPP Chapter 25	Chapter 21: Regulatory Cooperation	Chapter 28: Good Regulatory Practices
	Chapter 26: Transparency and Anti- Corruption	Incorporates TPP Chapter 26 (apart from TPP Annex 26-A, Art 3)	Chapter 27: Transparency	Chapter 29: Publication and Administration